Gene Therapy Showed Promise in Retinoschisis Trial

Atsena Therapeutics reported positive results from an ongoing clinical trial for X-linked retinoschisis.

Updated on Oct. 8, 2026 in Biotech

Gene Therapy Showed Promise in Retinoschisis Trial

Live Poll

Should medical research prioritize the development of new gene therapies for rare, incurable eye diseases?

Atsena Therapeutics has shared efficacy data from a phase 1/2/3 trial for its gene therapy candidate, ATSN-201, designed to treat X-linked retinoschisis. The results, presented at the American Academy of Ophthalmology, indicate that a specific dose met primary response criteria in a majority of treated patients.

Why it matters

The study aims to address X-linked retinoschisis, a condition affecting an estimated 30,000 patients across North America and Europe. Atsena identified a successful dose for the phase 3 portion of the trial that demonstrated consistent efficacy and tolerability.

Twelve of 18 total participants met optical coherence tomography (OCT) response criteria. OCT is a non-invasive imaging technique that uses light waves to take cross-section pictures of the retina.

The players

Atsena Therapeutics

A clinical-stage biotechnology company focused on developing adeno-associated virus-based gene therapies for inherited retinal diseases.

The details

The trial administered different doses and volumes of the gene therapy into one eye of patients suffering from X-linked retinoschisis, a genetic eye disorder that causes retinal layers to split. Researchers utilized microperimetry, a specialized test that measures the sensitivity of the retina to light, as the primary endpoint to gauge therapeutic success. The company selected the lowest administered dose for the phase 3 stage because it balanced effective retinal response with patient tolerability.

2025: Atsena shared initial safety data from the trial.
October 2026: Trial data was shared at the American Academy of Ophthalmology Meeting.
Q1 2027: Atsena expects to complete trial enrollment.
H1 2028: The company plans to report final trial data.
End of 2028: Atsena aims to file for FDA approval.

The Tech Race

This development marks a milestone for the ATSN-201 program as it advances toward potential regulatory filing by 2028. It situates Atsena Therapeutics within a competitive field of gene therapy developers targeting inherited retinal disorders.

Eight of the nine patients receiving the primary dose had baseline visual acuity worse than 20/40, the typical threshold for driving in the United States. Future patient access to this treatment depends on the completion of the phase 3 trial and successful regulatory approval.

The takeaway

The study demonstrates that ATSN-201 can elicit a measurable retinal response in patients with X-linked retinoschisis. Observers should monitor the company's progress toward the Q1 2027 enrollment completion goal as a signal of the trial's timeline viability.

What happens next

Atsena expects to complete enrollment in the third part of the study in the first quarter of 2027, followed by a data report in the first half of 2028.